ADIM
ASND icon

Alpha DNA Investment Management’s Ascendis Pharma A/S ASND Stock Holding History

Alpha DNA Investment Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,601
Closed -$768K – 174
2023
Q2 		$768K Buy
+8,601
New +$749K 0.26% 113

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alpha DNA Investment Management's ASND Position: Q3 2023 in Review

Alpha DNA Investment Management sold out of Ascendis Pharma A/S (ASND) in Q3 2023, closing a stake of 8,601 shares — an estimated $768K sold.

Alpha DNA Investment Management first reported a position in ASND in Q2 2023 and held it in 1 quarter. The position peaked at $768K in Q2 2023. 160 funds tracked by Wall St. Rank hold ASND as of Q3 2023.

  • Alpha DNA Investment Management reported no remaining Ascendis Pharma A/S position as of Q3 2023 after selling out during the quarter.
  • Alpha DNA Investment Management sold 8,601 Ascendis Pharma A/S shares in Q3 2023, an estimated $768K.
  • Alpha DNA Investment Management first reported a position in Ascendis Pharma A/S in Q2 2023 and held it in 1 quarter.
  • Alpha DNA Investment Management's Ascendis Pharma A/S position peaked at $768K in Q2 2023.
  • 160 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2023.

Based on Alpha DNA Investment Management's 13F filing for Q3 2023, filed 7 Nov 2023.